XML 43 R34.htm IDEA: XBRL DOCUMENT
v3.25.2

SEGMENT REPORTING (Tables) | 6 Months Ended
--- | ---
Mar. 31, 2025
SEGMENT REPORTING |
Schedule of segment information | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the six months ended March 31, 2025
​ | ​ | Diversified | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Pharmaceutical | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | and Allied | ​ | ​ | ​ | ​ | Insurance | ​ | ​ | ​
​ |  | Products* |  | AI Solutions |  | Business |  | Total
Revenue |  | $ | 9,631,184 |  | $ | 1,104,733 |  | $ | 3,575,497 |  | $ | 14,311,414
Cost of revenue | ​ |  | 8,283,104 | ​ |  | 772,807 | ​ |  | 2,744,070 | ​ |  | 11,799,981
Gross profit | ​ | $ | 1,348,080 | ​ | $ | 331,926 | ​ | $ | 831,427 | ​ | $ | 2,511,433
Depreciation and amortization | ​ | $ | 200,236 | ​ | $ | 146,125 | ​ | $ | 95,729 | ​ | $ | 442,090
Capital expenditures | ​ | $ | 1,035,722 | ​ | $ | 130,835 | ​ | $ | — | ​ | $ | 1,166,557
* | Due to the acquisition of THE Company, the revenue has been reclassified into three categories. Among them, diversified pharmaceutical and allied products includes the former oxytetracycline & licorice products and TCMD, fertilizer, and heparin products and sausage casing.
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the six months ended March 31, 2024
​ | ​ | Oxytetracycline | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | & Licorice | ​ | ​ | ​ | ​ | Heparin | ​ | ​ | ​
​ | ​ | products and | ​ | ​ | ​ | ​ | products and | ​ | ​ | ​
​ |  | TCMD |  | Fertilizer |  | Sausage casing |  | Total
Revenue |  | $ | 10,755,535 | ​ | $ | 159,199 | ​ | $ | 1,647,865 | ​ | $ | 12,562,599
Cost of revenue | ​ |  | 9,501,675 | ​ | ​ | 104,591 | ​ | ​ | 1,542,311 | ​ | ​ | 11,148,577
Gross profit | ​ | $ | 1,253,860 | ​ | $ | 54,608 | ​ | $ | 105,554 | ​ | $ | 1,414,022
Depreciation and amortization | ​ | $ | 444,832 | ​ | $ | 22,857 | ​ | $ | 87,083 | ​ | $ | 554,772
Capital expenditures | ​ | $ | 685,827 | ​ | $ | 23,771 | ​ | $ | 76,949 | ​ | $ | 786,547
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For six months ended March 31, 2023
​ | ​ | Oxytetracycline | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | & Licorice | ​ | ​ | ​ | ​ | Heparin | ​ | ​ | ​
​ | ​ | products and | ​ | ​ | ​ | ​ | products and | ​ | ​ | ​
​ |  | TCMD |  | Fertilizer |  | Sausage casing |  | Total
Revenue |  | $ | 18,521,112 | ​ | $ | 752,672 | ​ | $ | 9,889,832 | ​ | $ | 29,163,616
Cost of revenue | ​ |  | 16,622,793 | ​ | ​ | 365,813 | ​ | ​ | 9,880,264 | ​ | ​ | 26,868,870
Gross profit | ​ | $ | 1,898,319 | ​ | $ | 386,859 | ​ | $ | 9,568 | ​ | $ | 2,294,746
Depreciation and amortization | ​ | $ | 452,036 | ​ | $ | 22,123 | ​ | $ | 97,282 | ​ | $ | 571,441
Capital expenditures | ​ | $ | 2,570,090 | ​ | $ | 28,098 | ​ | $ | 3,933 | ​ | $ | 2,602,121
​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | March 31, |  | September 30,
​ | ​ | 2025 | ​ | 2024
Total Assets |  | ​ |  |  | ​ |
Diversified Pharmaceutical and Allied Products | ​ | $ | 154,006,779 | ​ | $ | 53,003,728
AI Solutions | ​ | $ | 22,499,030 | ​ | $ | —
Insurance Business | ​ | $ | 30,887,640 | ​ | $ | —
Total | ​ | $ | 207,393,449 | ​ | $ | 53,003,728
​

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration